Core Viewpoint - Entera Bio Ltd. is advancing its oral peptide therapy EB613 for osteoporosis, with two abstracts accepted for presentation at the upcoming WCO-IOF-ESCEO congress in April 2025, highlighting the company's commitment to addressing significant health concerns in osteoporosis treatment [1][4]. Group 1: Product Development - EB613 is being developed as the first once-daily oral anabolic PTH(1-34) tablet treatment aimed at high-risk post-menopausal women with osteoporosis [2][6]. - A Phase 2 study of EB613 showed a fast onset of action and significant increases in bone mineral density (BMD) across all skeletal sites, along with increased bone formation and reduced bone resorption [2][6]. - The company plans to initiate a Phase 3 registrational study for EB613 following FDA qualification of a quantitative BMD endpoint [7]. Group 2: Market Need and Impact - Osteoporosis poses a serious health risk, with an estimated 200 million women affected globally, and 50% of women and 20% of men over 50 at risk of fragility fractures [5]. - EB613 aims to provide a simple oral treatment option to address the treatment gap in current osteoporosis care, which often relies on injectable therapies [6]. Group 3: Presentation Details - The presentation titled "Effects of EB613 Tablets [Oral PTH(1-34)] on Trabecular and Cortical Bone Using 3D-DXA: Post-Hoc Results from Phase 2 Study" will be delivered as an oral presentation on April 11, 2025 [3]. - Another presentation, "EB613 Tablet Treatment [Oral PTH(1-34)] – Does PK Drive Bone Modeling Versus Bone Remodeling?" will be showcased as a poster from April 11 to April 13, 2025 [3].
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases